FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology

Lung Cancer

Volumn 35, Issue 2, 2002, Pages 179-187

  Ryu, Jin Sook ^a   Choi, Noah C ^a   Fischman, Alan J ^a   Lynch, Thomas J ^a   Mathisen, Douglas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemoradiotherapy; FDG PET; Non small cell lung cancer; Restaging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036160394     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00332-4     Document Type: Article

References (26)

1. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805
2. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer
3. Neoadjuvant therapy: A novel and effective treatment for stage IIIB non-small cell lung cancer
4. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study
5. CT and MR imaging in staging non-small cell bronchogenic carcinoma: Report of the Radiologic Diagnostic Group
6. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer
7. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning
8. Staging non-small cell lung cancer by whole-body positron emission tomographic mapping
9. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung cancer
10. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography
11. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung patients treated with radiotherapy: Preliminary findings
12. Fourine-18 deoxyglucose and false positive results: A major problem in the diagnostics of oncological patients
13. Potential impact on survival of improved downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer
14. Performance characteristics of an eight-ring whole body PET scanner
15. Regional lymph node classification for lung cancer staging
16. Overview by an oncologist: What are the imaging needs for the oncologist and oncological surgeon?
17. FDG-PET evaluation of therapeutic effects on VX2 liver tumor
18. Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: Preliminary study of lung cancer
19. PET studies of fluorodeoxy glucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy
20. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma
21. 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases
22. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma
23. Early changes in fluorine-18-FDG uptake during radiotherapy
24. The dose uptake ratio: Useful parameter of over simplification?
25. USV: Standard uptake or silly useless value?
26. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: Preliminary prospective evaluation